Becker's Healthcare October 5, 2020
Bristol Myers Squibb on Oct. 5 inked a $13.1 billion deal to buy Brisbane, Calif.-based drugmaker MyoKardia, aiming to diversify its drug portfolio beyond oncology medicines.
The New York City pharma giant will gain MyoKardia’s mavacamten, an experimental heart drug that treats obstructive hypertrophic cardiomyopathy. The treatment has not been approved by the FDA yet.
“We...